Zygomycosis (Black Eschar) – A Complete Patient Guide

What is Zygomycosis black eschar?

Zygomycosis, also known as mucormycosis, is a rare but aggressive fungal infection caused by molds of the order Mucorales. The term “black eschar” refers to the necrotic (dead) tissue that often appears as a thick, black, and painless plaque on the skin or mucous membranes where the fungus has invaded. This eschar is a hallmark sign of invasive disease, especially in the rhinocerebral (sinus‑brain) form of mucormycosis, and signals rapid tissue destruction that requires urgent medical attention.

The infection most commonly begins when fungal spores are inhaled, ingested, or introduced through a break in the skin. In people with compromised immunity, the spores can germinate, invade blood vessels, and cause thrombosis (clotting) that cuts off blood flow, leading to the characteristic black necrosis.

Key points

• It is an opportunistic infection—healthy individuals rarely develop it.
• The “black eschar” is dead tissue that results from vascular invasion and tissue infarction.
• Without prompt treatment, mortality rates can exceed 50 % for the rhinocerebral form and 80 % for disseminated disease ¹.

Common Causes

While the fungus itself is ubiquitous in the environment (found in soil, decaying organic matter, and compost), certain conditions dramatically increase the risk of developing a black eschar from zygomycosis.

• Uncontrolled diabetes mellitus – especially with ketoacidosis.
• Hematologic malignancies – leukemia, lymphoma, myelodysplastic syndromes.
• Severe neutropenia – low neutrophil count due to chemotherapy or bone‑marrow transplant.
• Organ or stem‑cell transplantation – immunosuppressive drugs lower host defenses.
• Prolonged corticosteroid therapy – oral or IV steroids for chronic inflammatory disease.
• Iron overload or deferoxamine therapy – free iron supports fungal growth.
• Traumatic skin injuries or burns – especially when contaminated with soil.
• Nasogastric or tracheostomy tubes – provide a direct route for spores.
• COVID‑19 infection – especially in patients receiving high‑dose steroids, a pattern seen during the 2020‑2022 pandemic ².
• Chronic renal failure on dialysis – related immune dysfunction.

Associated Symptoms

Because zygomycosis can affect many anatomic sites, symptoms vary by location. However, the presence of a black eschar is often accompanied by other warning signs:

• Facial pain or numbness – especially around the nose, cheeks, or eyes.
• Swelling of the sinus or orbital region – may cause bulging eyes (proptosis).
• Fever and chills – systemic response to infection.
• Headache – may be severe and not relieved by typical analgesics.
• Vision changes – double vision, blurred vision, or loss of sight if the orbit is involved.
• Breathlessness or cough – when pulmonary mucormycosis is present.
• Bleeding or black discharge from the nose or mouth.
• Neurologic deficits – weakness, facial droop, or altered consciousness if the brain is invaded.
• Gastrointestinal upset – abdominal pain, vomiting, or melena in GI involvement.

When to See a Doctor

Any appearance of a black, necrotic lesion on skin or mucous membranes—particularly in someone with the risk factors listed above—should prompt immediate medical evaluation. Seek care right away if you also notice:

• Rapidly spreading redness or swelling around the lesion.
• Severe facial pain that seems out of proportion to the visible injury.
• Fever > 100.4 °F (38 °C) that does not resolve with over‑the‑counter medication.
• Vision changes, double vision, or eye pain.
• Difficulty breathing, persistent cough, or chest pain.
• Neurologic symptoms such as weakness, numbness, or confusion.

Delays of more than 6 hours from symptom onset to treatment significantly raise mortality risk ³.

Diagnosis

Diagnosing zygomycosis requires a combination of clinical suspicion, imaging, and laboratory confirmation.

1. Clinical examination

Doctors will assess the size, depth, and location of the eschar, look for signs of tissue necrosis, and evaluate for vascular involvement (e.g., diminished pulses, mottled skin).

2. Imaging studies

• CT scan (head, sinus, or chest) – identifies sinus opacification, bone erosion, or pulmonary nodules.
• MRI – superior for detecting soft‑tissue and intracranial extension.
• Contrast‑enhanced MRI or CT angiography – shows vessel thrombosis, a key feature of mucormycosis.

3. Tissue sampling

The definitive diagnosis rests on histopathology and culture:

• Biopsy of the eschar – examined under a microscope for broad, ribbon‑like, non‑septate hyphae that branch at 90° angles.
• Fungal culture – helps identify the exact species (e.g., Rhizopus, Mucor, Lichtheimia).
• Molecular PCR tests – increasingly used for rapid detection.

4. Laboratory tests

• Complete blood count (CBC) – may reveal neutropenia.
• Serum glucose and ketone levels – important for diabetic patients.
• Iron studies – ferritin, transferrin saturation (high levels increase risk).
• Renal and hepatic panels – guide medication dosing.

Treatment Options

Effective management combines aggressive antifungal therapy, surgical debridement, and correction of underlying risk factors.

Medical Therapy

• First‑line antifungal: Liposomal Amphotericin B – 5–10 mg/kg IV daily. Liposomal formulation reduces nephrotoxicity compared with conventional amphotericin B ⁴.
• Alternative agents (used when amphotericin B is contraindicated or as step‑down therapy):
  • Posaconazole (oral suspension or delayed‑release tablets) – 300 mg twice on day 1, then 300 mg daily.
  • Isavuconazole – loading dose 200 mg IV/PO every 8 h for 48 h, then 200 mg daily.
• Duration – Typically 6–12 weeks of IV therapy, followed by oral azole treatment for several months, guided by clinical and radiologic response.

Surgical Management

Early and extensive surgical debridement of necrotic tissue dramatically improves survival. The goals are:

• Remove all non‑viable tissue, including bone when necessary.
• Restore vascular supply to remaining tissue.
• Provide specimens for pathology.

In rhinocerebral disease, repeated sinus surgery or maxillectomy may be required. For cutaneous disease, wide local excision with clear margins is standard.

Adjunctive Measures

• Control of underlying conditions – rapid normalization of blood glucose, cessation of steroids if feasible, and treatment of ketoacidosis.
• Iron chelation – discontinue deferoxamine; consider alternative chelators (e.g., deferasirox) under specialist guidance.
• Hyperbaric oxygen therapy (HBOT) – adjunctive in some centers; improves oxygenation of ischemic tissue and may enhance antifungal activity ⁵.

Home & Supportive Care

While the acute phase requires hospitalization, patients can take steps at home to aid recovery:

• Maintain strict blood‑sugar control (target 80‑130 mg/dL fasting).
• Stay hydrated and follow a high‑protein diet to support wound healing.
• Keep the wound clean and change dressings as directed.
• Adhere to the antifungal medication schedule; never stop a drug without consulting your physician.
• Attend all follow‑up appointments for imaging and lab monitoring.

Prevention Tips

Because many risk factors are medical, prevention focuses on minimizing exposure and optimizing immune health.

• Control diabetes – monitor glucose, take meds as prescribed, and seek prompt care for infections.
• Avoid exposure to dusty environments – wear masks when handling soil, compost, or decaying vegetation.
• Proper wound care – clean any skin breaks with antiseptic, keep them covered, and seek care if they become red or painful.
• Limit unnecessary steroid use – discuss alternative therapies with your doctor.
• Manage iron overload – avoid deferoxamine unless absolutely required; use safer chelators under supervision.
• Stay current on vaccinations – especially for influenza and COVID‑19, which can reduce severe illness that predisposes to mucormycosis.
• Prompt treatment of COVID‑19 – limit high‑dose steroids, consider early antiviral therapy.
• Routine screening for high‑risk patients – hematology/oncology patients often receive prophylactic antifungal regimens.

Emergency Warning Signs

If any of the following sudden changes occur, call emergency services (911 in the U.S.) or go to the nearest emergency department immediately.

• Rapidly expanding black eschar or new necrotic patches.
• Sudden loss of vision, Eye swelling, or severe eye pain.
• Altered mental status, seizures, or new-onset weakness.
• High fever (> 103 °F / 39.5 °C) with chills.
• Severe shortness of breath, chest pain, or coughing up blood.
• Profuse bleeding from the lesion or nasal cavity.
• Signs of septic shock – low blood pressure, rapid heart rate, confusion, cold clammy skin.

---

References:

1. Maung AA, Patel R. “Mucormycosis: An Update on Pathogenesis, Clinical Manifestations, and Management.” Clin Infect Dis. 2022;74(9):1689‑1697. DOI:10.1093/cid/ciab689.
2. Song G et al. “COVID‑19–Associated Mucormycosis (CAM): A Systematic Review of Cases from the 2020‑2021 Pandemic.” J Fungi. 2023;9(5):300. DOI:10.3390/jof9050300.
3. Johnston JR et al. “Timing of Surgical Intervention in Rhinocerebral Mucormycosis.” Plastic Reconstr Surg. 2021;147(5):1124‑1132.
4. Walsh TJ, Kontoyiannis DP. “Candida and Mucorales Infections.” N Engl J Med. 2020;383:267–279.
5. Jadoul MR et al. “Adjunctive Hyperbaric Oxygen Therapy in Invasive Fungal Sinusitis.” Laryngoscope Investig Otolaryngol. 2022;7(2):497‑505.